A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Suzetrigine (SUZ) to see how effective and safe it is for managing acute pain after aesthetic or reconstructive surgeries. The goal is to find out if SUZ can help patients feel better as part of a combination treatment plan, reducing the need for stronger pain medications like opioids after surgery.

To be eligible for this trial, participants should be between the ages of 65 and 74 and have a body mass index (BMI) between 18 and 40, which is a measure of body weight in relation to height. They must also be scheduled for a surgery that usually requires pain management for at least three days afterward. If you join the study, you can expect to receive SUZ along with other treatments to help manage your pain. It's important to note that individuals who have previously participated in a study with SUZ or have received a specific medication called Journavx will not be able to participate. This trial is not yet recruiting participants, so keep an eye out for updates if you're interested!

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Body mass index (BMI) of greater than or equal to (≥)18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
• • Participants scheduled to undergo an aesthetic or reconstructive surgical procedure that would typically be treated with opioid therapy for at least 72 hours postoperatively
• Key Exclusion Criteria:
• • • Participated in a previous study with SUZ or received Journavx
• • Other protocol defined Inclusion/Exclusion criteria may apply.